JPMorgan Chase & Co. Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $575.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective increased by JPMorgan Chase & Co. from $495.00 to $575.00 in a report published on Friday, Benzinga reports. The firm currently has an overweight rating on the medical equipment provider’s stock.

ISRG has been the subject of several other research reports. Redburn Atlantic raised shares of Intuitive Surgical from a neutral rating to a buy rating and increased their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Truist Financial raised their price target on Intuitive Surgical from $450.00 to $515.00 and gave the company a buy rating in a report on Tuesday, July 16th. Piper Sandler upped their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an overweight rating in a report on Friday, July 19th. Robert W. Baird raised their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an outperform rating in a report on Friday, July 19th. Finally, Citigroup upped their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a buy rating in a research note on Thursday, August 22nd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of Moderate Buy and a consensus price target of $467.55.

Intuitive Surgical Stock Up 0.6 %

NASDAQ ISRG opened at $487.61 on Friday. Intuitive Surgical has a twelve month low of $254.85 and a twelve month high of $496.48. The business has a 50-day moving average price of $481.33 and a 200-day moving average price of $435.81. The firm has a market cap of $172.96 billion, a price-to-earnings ratio of 88.02, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Research analysts expect that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the transaction, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several large investors have recently modified their holdings of ISRG. One Wealth Management Investment & Advisory Services LLC raised its stake in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares in the last quarter. Daymark Wealth Partners LLC raised its position in shares of Intuitive Surgical by 0.3% in the 3rd quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock worth $3,452,000 after acquiring an additional 24 shares in the last quarter. Indiana Trust & Investment Management CO lifted its stake in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 25 shares during the last quarter. Hoxton Planning & Management LLC boosted its position in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 25 shares in the last quarter. Finally, True North Advisors LLC grew its stake in Intuitive Surgical by 2.1% in the third quarter. True North Advisors LLC now owns 1,232 shares of the medical equipment provider’s stock valued at $605,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.